The Definitive Guide to BPC-157
By BPC-157peptide.org Research Team Reviewed by Purely Peptides Research Dept. Published Last reviewedBody Protection Compound-157 is a synthetic 15-amino-acid peptide derived from human gastric juice with potent cytoprotective, angiogenic, and tissue-repair properties demonstrated across 100+ preclinical studies.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — that is a partial sequence of a protein known as Body Protection Compound, which is naturally found in human gastric juice. It was first isolated and characterized by Professor Predrag Sikirić and colleagues at the University of Zagreb in the early 1990s.[1]
Unlike many peptides, BPC-157 exhibits remarkable stability in human gastric juice and does not require a carrier molecule for biological activity. Its amino acid sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — is stable at room temperature, resistant to enzymatic degradation, and demonstrates biological activity through both oral and injectable routes of administration.[2]
In preclinical models, BPC-157 has demonstrated a broad spectrum of cytoprotective and healing effects across multiple organ systems, including the gastrointestinal tract, musculoskeletal system, vascular endothelium, central and peripheral nervous systems, and various soft tissues.
Origin & Discovery
BPC-157 was derived from the isolation of proteins from human gastric juice. Researchers identified a larger protein complex with potent protective properties against gastric ulceration. The 15-amino-acid fragment (BPC-157) retained the protective activity of the parent compound while offering greater stability and simpler synthesis. This peptide has no known homology to any other known bioactive peptide, making it pharmacologically unique.[1]
Why Researchers Are Interested
BPC-157 has attracted significant attention across the biomedical research community because it appears to modulate multiple healing pathways simultaneously rather than acting on a single molecular target. Its pleiotropic effects, combined with an exceptionally favorable safety profile observed in rodent LD-50 toxicity studies (where no lethal dose has been established), make it a candidate of considerable interest for further translational research.[3]
Mechanisms of Action
BPC-157 exerts its biological effects through multiple interconnected signaling pathways, distinguishing it from single-target therapeutics.
Nitric Oxide (NO) System Modulation
BPC-157 interacts with the nitric oxide system to promote vasodilation and angiogenesis. Studies demonstrate it upregulates eNOS (endothelial nitric oxide synthase) expression, enhancing local blood flow to injured tissue. This NO-mediated pathway is central to its wound healing and gastroprotective effects and has been confirmed in multiple NO-blocker studies (L-NAME, L-NOARG).[4][5]
Angiogenesis & VEGF Upregulation
A key mechanism of BPC-157's tissue-repair activity is the promotion of new blood vessel formation. The peptide has been shown to upregulate vascular endothelial growth factor (VEGF) receptor expression (VEGFR2) and promote the VEGF signaling cascade, stimulating granulation tissue formation and accelerating revascularization of damaged tissue.[6]
Growth Factor Modulation
BPC-157 influences the expression and signaling of several growth factors critical to tissue repair, including epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor-beta (TGF-β), and fibroblast growth factor (FGF). This broad growth-factor modulation contributes to its cross-tissue efficacy — from tendon and ligament repair to mucosal regeneration.[7][8]
FAK-Paxillin Pathway Activation
BPC-157 activates the focal adhesion kinase (FAK)–paxillin signaling cascade, which is critical for cell migration, adhesion, and wound closure. Phosphorylation of FAK promotes cytoskeletal reorganization and directed cell movement into wound sites. This has been demonstrated in tendon fibroblast, endothelial cell, and intestinal epithelial cell models.[9]
Dopaminergic & GABAergic Interaction
BPC-157 has demonstrated significant interactions with the central dopamine system. It can counteract the behavioral effects of both dopamine agonists and antagonists, suggesting a modulatory (stabilizing) role rather than simple agonism or antagonism. It also interacts with the GABAergic and serotonergic systems, showing anxiolytic and antidepressant-like effects in rodent models.[10][11]
Anti-Inflammatory Cascades
BPC-157 modulates the inflammatory response by influencing cytokine expression, reducing pro-inflammatory mediators (TNF-α, IL-6, IL-1β), and shifting the balance toward resolution of inflammation. It has been shown to inhibit mast cell degranulation and reduce neutrophil infiltration in various models of tissue injury and inflammation.[12]
Key Research Studies
A selection of peer-reviewed studies investigating BPC-157's effects across multiple organ systems and pathological models.
| Study / Authors | Year | Type | Key Finding | PMID / DOI |
|---|---|---|---|---|
| Seiwerth et al. — BPC 157 and Standard Angiogenic Growth Factors | 2018 | Review | Comprehensive review of BPC-157's interaction with VEGF, EGF, FGF and NO system in wound healing models | 29898106 |
| Staresinic et al. — Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon | 2003 | In Vivo | BPC-157 significantly accelerated Achilles tendon healing with improved biomechanical properties vs. controls | 14562198 |
| Chang et al. — BPC 157 promotes muscle healing | 2011 | In Vivo | Enhanced recovery of crushed rat muscle via upregulation of GH receptor expression in muscle tissue | 21030672 |
| Sikiric et al. — Brain-gut axis and pentadecapeptide BPC 157 | 2017 | Review | Reviewed BPC-157's effects on the brain-gut axis, dopamine/serotonin system interaction, and neuroprotective properties | 27913366 |
| Sebecic et al. — Osteogenic effect of BPC 157 on healing of segmental bone defect | 1999 | In Vivo | Demonstrated enhanced bone healing and osteogenic activity in rabbit segmental bone defect models | 10451352 |
| Sikiric et al. — The pharmacological properties of the novel peptide BPC 157 | 1994 | Review | Original characterization of BPC-157's anti-ulcer activity, cytoprotection mechanisms, and safety profile — foundational paper | 7513449 |
| Cesarec et al. — BPC 157 and methyldigoxin-induced arrhythmias | 2013 | In Vivo | BPC-157 prevented and reversed digoxin-induced cardiac arrhythmias in rat models, suggesting cardioprotective effects | 23912175 |
| Sikiric et al. — Stable gastric pentadecapeptide BPC 157 — NO system relation | 2020 | Review | Comprehensive analysis of BPC-157's interaction with the nitric oxide system across injury models | 32067607 |
| Hsieh et al. — BPC-157 treatment of corneal alkali burn | 2017 | In Vivo | Topical BPC-157 application reduced corneal opacity and neovascularization in alkali-burned rat corneas | 28340236 |
| Tkalcevic et al. — Enhancement of nerve, blood vessel, and tendon recovery by BPC 157 | 2007 | In Vivo | Demonstrated simultaneous healing enhancement across nerves, blood vessels, and tendons in transected rat models | 17713705 |
| Sikiric et al. — Counteraction of alcohol intoxication and dependence with BPC 157 | 2016 | In Vivo | BPC-157 reduced alcohol intake, prevented alcohol-induced gastric lesions, and attenuated withdrawal symptoms in rat models | 27085524 |
| Vukojevic et al. — Pentadecapeptide BPC 157 and traumatic brain injury | 2020 | In Vivo | BPC-157 improved functional recovery and reduced brain edema and hemorrhage following TBI in rats | 31989845 |
Dosing & Administration
The following dosing information is compiled from preclinical data and anecdotal community protocols. No human clinical trials have established definitive dosing guidelines. This is for informational purposes only.
Subcutaneous Injection
Most common research routeOral Administration
Gastric stability advantageReconstitution Guide
Preparation essentialsSafety & Tolerability
BPC-157 has demonstrated an exceptionally favorable safety profile in preclinical studies. No LD-50 (median lethal dose) has been established even at extremely high dosages in rodent models.
🟢 Observed Safety Data
- No LD-50 has been reached in toxicity studies — even at doses orders of magnitude above effective therapeutic ranges[3]
- No reported organ toxicity in subchronic and chronic dosing studies in rats
- No observed mutagenic or carcinogenic activity in available preclinical data
- No significant alterations in blood chemistry, hematology, or organ histology at therapeutic doses
- Stability in gastric juice suggests favorable oral bioavailability profile without enteric coating
- No observed interaction with cytochrome P450 enzymes in available data, suggesting low drug-interaction potential
⚠️ Important Considerations
- No completed human clinical trials — all safety data is preclinical (rodent/animal models)
- Long-term effects of exogenous BPC-157 administration in humans remain unknown
- The peptide's pro-angiogenic activity is a theoretical concern in the context of pre-existing cancers — angiogenesis supports tumor vascularization
- Quality and purity of commercially sourced BPC-157 varies dramatically — third-party COA (Certificate of Analysis) verification is essential
- BPC-157 is not approved by the FDA, EMA, or any regulatory body for human therapeutic use
- Individuals on anticoagulants, cardiovascular medications, or undergoing cancer treatment should exercise particular caution
Researched Applications
Gastrointestinal Protection & Healing
BPC-157 was originally characterized for its potent anti-ulcer activity. It has demonstrated protective and healing effects against gastric ulcers induced by NSAIDs (including aspirin, diclofenac, and ibuprofen), alcohol, restraint stress, cysteamine, and various necrotizing agents. Its gastroprotective mechanism involves mucosal prostaglandin enhancement, NO system modulation, and direct cytoprotection of gastric epithelial cells. BPC-157 also shows efficacy in models of inflammatory bowel disease (IBD), including experimentally induced colitis and intestinal anastomosis healing.[1][2]
Musculoskeletal Tissue Repair
Among the most widely researched applications, BPC-157 has shown accelerated healing in transected Achilles tendons, medial collateral ligaments (MCL), crushed muscles, and segmental bone defects. The mechanism involves upregulation of growth hormone receptors in muscle, enhanced collagen deposition, and improved biomechanical properties (tensile strength) of healed tissue. Multiple groups have independently replicated these findings across different injury models.[6][7][8]
Neuroprotection & CNS Effects
BPC-157 interacts with both the central and peripheral nervous systems. Preclinical studies have demonstrated neuroprotective effects following traumatic brain injury, peripheral nerve transection, and NSAID-induced encephalopathy. The peptide also modulates dopaminergic activity — counteracting both the hyperactivity caused by amphetamines and the catalepsy caused by haloperidol — suggesting a stabilizing rather than directional effect on dopamine signaling.[10][11]
Cardiovascular & Vascular Effects
BPC-157 has shown cardioprotective properties in several models, including protection against digitalis-induced arrhythmias, improved outcomes following pulmonary hypertension induction, and enhanced wound healing after vascular injury. Its interaction with the NO system and pro-angiogenic properties appear central to these cardiovascular effects.[4][5]
Hepatoprotective Effects
Studies demonstrate BPC-157's ability to protect against liver damage induced by alcohol, NSAIDs, and various hepatotoxic agents. It has also shown efficacy in counteracting liver cirrhosis and hepatic encephalopathy in animal models, with proposed mechanisms including anti-oxidant activity, anti-inflammatory cytokine modulation, and enhanced hepatocyte regeneration.[12]
Common Questions
What is BPC-157 and what is it used for in research?
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice protein BPC. In preclinical research it is studied for tissue repair, tendon and ligament healing, gastrointestinal mucosal protection, neuroprotection, and angiogenesis modulation across animal models.
What is the purity standard for research-grade BPC-157?
Research-grade BPC-157 should meet ≥98% purity verified by HPLC analysis and confirmed by mass spectrometry. A Certificate of Analysis (COA) from a third-party laboratory is the minimum acceptable documentation for any research application.
How is BPC-157 stored to maintain stability?
Lyophilized BPC-157 should be stored at −20°C away from light and moisture. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 14–28 days. Repeated freeze-thaw cycles degrade peptide integrity.
What is the difference between lyophilized and reconstituted BPC-157?
Lyophilized BPC-157 is freeze-dried powder stable for months at −20°C. Reconstituted BPC-157 is dissolved in bacteriostatic water and is active but degrades within weeks. Lyophilized form has far superior shelf life for research inventory.
Has BPC-157 been tested in human clinical trials?
No completed human clinical trials for BPC-157 have been published as of 2026. All available efficacy and safety data is from preclinical rodent and animal models. It is not approved by the FDA or any regulatory body for human therapeutic use.
What reconstitution volume should be used for BPC-157?
For a 5mg vial, adding 2mL bacteriostatic water yields a 2.5mg/mL concentration. A 250mcg dose equals 0.1mL (10 units on an insulin syringe). Adjust volume to your target concentration and syringe type.
Lyophilized vs. Reconstituted BPC-157 Stability
Get Research-Grade BPC-157
We provide third-party tested, >98% purity BPC-157 peptide. Contact us directly through Telegram or email to place an order or ask questions.
Purely Peptides
Research-grade peptides with verified purity. Every batch comes with a third-party Certificate of Analysis (COA). Reach out directly — we respond quickly.
Quality Guarantee: All products are sold strictly as research compounds. We provide COA documentation with HPLC purity analysis and mass spectrometry verification for every batch.
Scan to Connect on Telegram
Open your camera app or Telegram scanner to instantly reach us.
@PURELY_PEPTIDES
⚠ Research Use Disclaimer
BPC-157 is sold exclusively as a research compound. It is not approved by the FDA or any regulatory agency for human consumption, therapeutic use, or medical treatment. The information provided on this website is compiled from published preclinical research and is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. No statements on this website have been evaluated by the FDA. Consult a qualified healthcare professional before making any decisions regarding peptide research or personal health protocols. By using this website or purchasing products, you acknowledge that you understand these compounds are intended for in-vitro research and laboratory use only.
BPC-157 Stability Reference Data
Original compiled data from published stability studies and peer-reviewed handling protocols.
| Storage Condition | Estimated Stability | Notes |
|---|---|---|
| −80°C (ultra-frozen, sealed) | 36+ months | Maximum stability; research archive standard |
| −20°C (frozen, sealed, dark) | 24–36 months | Optimal for routine lab storage |
| 4°C (refrigerated, sealed) | 6–12 months | Acceptable for short-term inventory |
| 25°C (room temperature) | 1–3 months | Not recommended; transit/shipping only |
| 37°C | Days to weeks | Significant degradation; avoid |
| Any temp — UV/light exposure | Significantly reduced | Peptide bond photodegradation; amber vials required |
| Condition | Estimated Stability | Notes |
|---|---|---|
| 4°C in bacteriostatic water | 3–4 weeks | Standard protocol; benzyl alcohol inhibits bacterial growth |
| 4°C in sterile water | 1–2 weeks | No bacteriostatic preservative; faster degradation |
| −20°C, single-use aliquots | 3–6 months | Freeze before use; never re-freeze after thaw |
| Room temp (any diluent) | 24–72 hours | Emergency use only |
| Repeated freeze-thaw cycles | Rapidly degrades | Causes aggregation and structural damage; aliquot to prevent |
| BW Volume Added | Concentration | Per 0.1mL (10 IU) | Per 0.5mL (50 IU) |
|---|---|---|---|
| 1.0 mL | 10,000 mcg/mL | 1,000 mcg | 5,000 mcg |
| 2.0 mL | 5,000 mcg/mL | 500 mcg | 2,500 mcg |
| 4.0 mL | 2,500 mcg/mL | 250 mcg | 1,250 mcg |
| 10.0 mL | 1,000 mcg/mL | 100 mcg | 500 mcg |
| 20.0 mL | 500 mcg/mL | 50 mcg | 250 mcg |
| Degradation Factor | Mechanism | Mitigation |
|---|---|---|
| UV / light exposure | Photolytic peptide bond cleavage | Amber vials; dark storage always |
| Repeated freeze-thaw | Aggregation; structural denaturation | Pre-aliquot into single-use volumes |
| Acidic pH (<4.5) | Asp/Glu residue instability; hydrolysis | Maintain pH 5.0–7.5; use BW or sterile saline |
| Alkaline pH (>8.0) | Peptide backbone hydrolysis | Avoid high-pH diluents |
| Elevated temperature | Arrhenius-accelerated degradation | Always refrigerate reconstituted peptide |
| Metal ion contamination | Oxidative side-chain degradation | Use pharmaceutical-grade diluents only |
Sourcing High-Purity BPC-157 for Laboratory Research
The reproducibility of BPC-157 research depends critically on compound purity and accurate concentration. Degraded or underdosed material produces unreliable results that cannot be compared against published literature. For researchers requiring third-party tested BPC-157 with documented purity, Purely Peptides provides independently verified research-grade material.
All compounds are sold strictly for in vitro and laboratory research use only. Not for human administration.